The new face of monkeypox virus: an emerging global emergency
Nityanand Jain, Edouard Lansiaux, Raimonds Simanis
New Microbes and New Infections, doi:10.1016/j.nmni.2022.100989
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez, None
Biber, Mandelboim, Harmelin, Ram, Shaham, Favorable outcome on viral load and culture viability using Ivermectin in early treatment of nonhospitalized patients with mild COVID-19 -A double-blind, randomized placebo-controlled trial, medRxiv
Bray, Rayner, Noel, Jans, Wagstaff, Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Caly, Wagstaff, Jans, Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?, Antiviral Res
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med
Hill, Mirchandani, Pilkington, Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud, Open Forum Infect Dis
Lopez-Medina, Lopez, Hurtado, Davalos, Ramirez et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA
Reis, Silva, Silva, Thabane, Milagres et al., Effect of Early Treatment with Ivermectin among Patients with Covid-19, N Engl J Med
Reyes, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Santin, Scheim, Mccullough, Yagisawa, Borody, Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19, New Microbes New Infect
Vallejos, Zoni, Bangher, Villamandos, Bobadilla et al., Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial, BMC Infect Dis
Zaidi, Dehgani-Mobaraki, The mechanisms of action of ivermectin against SARS-CoV-2-an extensive review, J Antibiot
DOI record:
{
"DOI": "10.1016/j.nmni.2022.100989",
"ISSN": [
"2052-2975"
],
"URL": "http://dx.doi.org/10.1016/j.nmni.2022.100989",
"alternative-id": [
"S2052297522000415"
],
"article-number": "100989",
"author": [
{
"affiliation": [],
"family": "Schwartz",
"given": "Eli",
"sequence": "first"
}
],
"container-title": "New Microbes and New Infections",
"container-title-short": "New Microbes and New Infections",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
5,
27
]
],
"date-time": "2022-05-27T03:24:37Z",
"timestamp": 1653621877000
},
"deposited": {
"date-parts": [
[
2022,
5,
27
]
],
"date-time": "2022-05-27T03:24:38Z",
"timestamp": 1653621878000
},
"indexed": {
"date-parts": [
[
2022,
5,
27
]
],
"date-time": "2022-05-27T03:41:26Z",
"timestamp": 1653622886130
},
"is-referenced-by-count": 0,
"issued": {
"date-parts": [
[
2022,
5
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
5,
1
]
],
"date-time": "2022-05-01T00:00:00Z",
"timestamp": 1651363200000
}
},
{
"URL": "http://creativecommons.org/licenses/by/4.0/",
"content-version": "vor",
"delay-in-days": 22,
"start": {
"date-parts": [
[
2022,
5,
23
]
],
"date-time": "2022-05-23T00:00:00Z",
"timestamp": 1653264000000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S2052297522000415?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S2052297522000415?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "100989",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2022,
5
]
]
},
"published-print": {
"date-parts": [
[
2022,
5
]
]
},
"publisher": "Elsevier BV",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S2052297522000415"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Infectious Diseases",
"Microbiology"
],
"subtitle": [],
"title": "Does ivermectin have a place in the treatment of mild Covid-19?",
"type": "journal-article"
}
